303 related articles for article (PubMed ID: 37337241)
1. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
[TBL] [Abstract][Full Text] [Related]
2. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ; Chen PY; Fang YJ; Bair MJ; Chen CC; Chen CC; Yang TH; Lee JY; Yu CC; Kuo CC; Chiu MC; Chou CK; Chen CY; Hu WH; Tsai MH; Hsu YC; Shun CT; Luo JC; Lin JT; El-Omar EM; Wu MS; Liou JM;
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):623-634. PubMed ID: 37178702
[TBL] [Abstract][Full Text] [Related]
3. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a 2-week therapy with levofloxacin concomitant versus a levofloxacin sequential regimen for Helicobacter pylori infection in the Syrian population: a study protocol for randomized controlled trial.
Alhalabi M; Almokdad R
Trials; 2024 Jan; 25(1):55. PubMed ID: 38225650
[TBL] [Abstract][Full Text] [Related]
5. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
Prapitpaiboon H; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
[TBL] [Abstract][Full Text] [Related]
6. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y
Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
[TBL] [Abstract][Full Text] [Related]
7. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
[TBL] [Abstract][Full Text] [Related]
8. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
9. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
10. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
11. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
[TBL] [Abstract][Full Text] [Related]
12. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H
Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Ji CR; Liu J; Li YY; Qiao C; Qu JY; Hu JN; Lin MJ; Ji R; Li LX; Zuo XL; Li YQ
J Dig Dis; 2020 Oct; 21(10):549-557. PubMed ID: 32833285
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.
Luo L; Huang Y; Liang X; Ji Y; Yu L; Lu H
Helicobacter; 2020 Aug; 25(4):e12699. PubMed ID: 32428369
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
Su J; Zhou X; Chen H; Hao B; Zhang W; Zhang G
Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505
[TBL] [Abstract][Full Text] [Related]
18. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
19. Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first-line treatment of Helicobacter pylori infection.
Li CL; Zhou K; Zhang YX; Suo BJ; Tian XL; Zhang YX; Ren XL; Shi YY; Zhou LY; Song ZQ
J Dig Dis; 2024 Jan; 25(1):36-43. PubMed ID: 38323705
[TBL] [Abstract][Full Text] [Related]
20. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
